Sargent Investment Group LLC lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 10.8% during the third quarter, HoldingsChannel.com reports. The firm owned 109,300 shares of the company’s stock after selling 13,280 shares during the period. Sargent Investment Group LLC’s holdings in Teva Pharmaceutical Industries were worth $1,970,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in TEVA. New Covenant Trust Company N.A. acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at about $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $30,000. UMB Bank n.a. increased its position in Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $48,000. Finally, Byrne Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $52,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Stock Down 1.2 %
Shares of TEVA traded down $0.20 during trading hours on Thursday, hitting $16.74. The company had a trading volume of 1,705,396 shares, compared to its average volume of 9,220,767. The company’s fifty day moving average price is $17.84 and its two-hundred day moving average price is $17.20. Teva Pharmaceutical Industries Limited has a one year low of $8.64 and a one year high of $19.31. The company has a market capitalization of $18.96 billion, a PE ratio of -19.76, a price-to-earnings-growth ratio of 1.34 and a beta of 0.87. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.
Wall Street Analyst Weigh In
Get Our Latest Analysis on TEVA
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Recommended Stories
- Five stocks we like better than Teva Pharmaceutical Industries
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- ETF Screener: Uses and Step-by-Step Guide
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.